Hologic (HOLX -1.5%) slips on a mixed FQ1 result late yesterday, beating on a per share basis...

|By:, SA News Editor

Hologic (HOLX -1.5%) slips on a mixed FQ1 result late yesterday, beating on a per share basis but coming up just shy on the revenue side. Net profit plunged as the health- products company posted higher acquisition-related charges which masked strong revenue growth. Revenue from its breast-health segment grew by 2.5%, mostly on the growing installed base of the company's digital mammography systems, while its diagnostics revenue soared to $305.9M from $154.1M the year prior, getting a big boost from its Gen-Probe acquisition.